AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 42 min read$CRL

Charles River: Q3 Earnings Snapshot

Charles River Laboratories (CRL) reported Q3 net income of $333.1M, or $6.86 per share. Adjusted earnings were $3.09 per share, exceeding analyst estimates of $2.98 per share. Revenue was $982.7M, surpassing expectations of $956.8M. The company expects full-year earnings between $11.35 and $11.55 per share.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 12:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Charles River: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CRLBullishHigh
01

Why it matters

The earnings beat and raised guidance suggest continued demand for CRO services, supporting sector momentum.

02

Market read

Fresh earnings data provides a clear catalyst for short‑term trading decisions on CRL and related CRO stocks.

03

What to watch

Potential headwinds from regulatory changes or client budget constraints could temper upside.

Relevance 8/10Novelty 8/10Timing: after release today

Background

Charles River Laboratories is a leading provider of preclinical and clinical laboratory services.

Company-level read

Ticker impact

$CRLBullishHigh confidence
Context

Charles River Laboratories reported Q3 earnings that beat expectations and raised full-year guidance.

Expected impact

upward pressure as the market prices in the earnings beat and higher guidance

Evidence & confidence

The surprise earnings beat and raised guidance are fresh, material information that traders can act on immediately.

Market effects

Sector

Strong earnings may lift the broader contract research organization (CRO) sector.

Regional

Positive for U.S. biotech and life‑science service providers.

Global

Reinforces confidence in global pharma outsourcing demand.

Counterpoint

What could challenge this read

If the market had already priced in a strong quarter, the beat may be muted.

Key entities

  • company
    Charles River Laboratories International Inc.

    Provider of medical research equipment and services.

Read at source← All news

StoryCharles River Laboratories reports Q3 2026 earnings beat and raises 2026 outlook

Also covered by

6 outlets

Related articles

NOV 4
$CRLMedAI 8/10

Charles River Q3 2026 slides: organic growth returns but stock falls

Charles River Laboratories (CRL) reported Q3 2026 results with 4.7% organic revenue growth and non-GAAP EPS of $3.09, beating estimates. Despite this, shares fell 5.88% due to concerns over margin sustainability and delayed pricing power recovery. Revenue was $982.7M, with non-GAAP operating margin expanding to 23.0%. The DSA segment saw 5.9% organic growth, while Manufacturing grew 7.4% organically. Management expects pricing benefits to materialize in late 2027.

investing.com6 min
NOV 4
$CRLMedAI 8/10

Charles River Laboratories 2026: Revenue $982.73M, EPS $6.86— 10-Q Summary

Charles River Laboratories reported Q3 2026 revenue of $982.73M, down 2.2% YoY, while net income rose to $333.07M and EPS increased to $6.86. Management cited improving demand in Discovery and Safety Assessment, portfolio changes, and cost savings. Nine-month revenue declined 1.3%, with growth in microbial testing and China model sales. The company completed divestitures and acquisitions, targeting $300M in annual savings by 2026.

tradingview.com1 min
NOV 4
$CRLMed

Charles River Laboratories Lifts Annual Outlook- Update

Charles River Laboratories (CRL) raised its 2026 outlook, expecting revenue to decline 1.5%-2.0% (previously 2.5%-3.5%) and organic revenue to grow at least 1.5% (previously 0%-1%). EPS estimates increased to $8.15-$8.35 from $3.05-$3.35, with non-GAAP EPS at $11.35-$11.55. Q3 profit rose to $333.07M ($6.86/share) due to a $245.6M tax benefit, while revenue fell 2.1% to $982.732M. Shares dropped nearly 4% in pre-market trading.

rttnews.com2 min